3 ms·
> Though substantial progress was being made, Pfizer decided to pull support ... [t]he “gliptin” class of drugs peaked at annual revenues of around $10 billion
by ClarityJones 2y ago
> Though substantial progress was being made, Pfizer decided to pull support ... [t]he “gliptin” class of drugs peaked at annual revenues of around $10 billion and remains a major oral therapy for type 2 diabetes.
- ClarityJones 2y ago> Pfizer found other routes to remain successful (some, such as their mRNA COVID19 vaccine, also in-licensed from smaller companies). > Even the biggest blockbusters can be dismissed ... by ... ambitious people, ... because ... ideas of how the market will react... . > These same dynamics are undoubtedly playing out today [seemingly referring to previous statements on their COVID-19 vaccine], and it will likely take decades to determine just how costly some of today’s mistakes will prove to be.
- nrb 2y ago> then the implication is that they released the mRNA vaccine because it too would increase disease (and thus avenues for profitability) Sure, a disease that kills a patient very quickly is bad for business. Better for them to be alive and fall ill later on from a laundry list of profitable ailments.